Skip to main content

CORRECTION article

Front. Immunol., 07 June 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.952446

Corrigendum: The Significance of Transarterial Chemo(embolization) Combined With Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

This article is a correction to:

  1. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

    1. Read original article
Qiao Ke,&#x;Qiao Ke1,2†Fuli Xin,&#x;Fuli Xin1,2†Huipeng Fang&#x;Huipeng Fang2†Yongyi Zeng*Yongyi Zeng1*Lei Wang,*Lei Wang2,3*Jingfeng Liu,*Jingfeng Liu4,5*
  • 1Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
  • 2College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian, China
  • 3Department of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
  • 4Department of Hepatopancreatobiliary Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
  • 5The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

A Corrigendum on:
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

By Ke Q, Xin F, Fang H, Zeng Y, Wang L and Liu J (2022) Front. Immunol.13:913464. doi:  .10.3389/fimmu.2022.913464

In the original article, references 47 and 48 was incorrectly inserted as

47: Wang YY, Wang LJ, Xu D, Liu M, Wang HW, Wang K, et al. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. HPB (Oxford) (2019) 21(4):425-33. doi: 10.1016/j.hpb.2018.08.001;

48: Wang L, Ke Q, Deng M, Huang X, Zeng J, Liu H, et al. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma after radical hepatectomy: a real world study. Scand J Gastroenterol (2019) 54(11):1403-11. doi: 10.1080/00365521.2019.1684986”.

The correct references are as follows:

47: Zhang WW, Hu BY, Han J, Wang HG, Wang ZB, Ye HY, et al. A Real-World Study of PD-1 Inhibitors Combined With TKIs for HCC With Major Vascular Invasion as the Conversion Therapy: A Prospective, Non-Randomized, Open-Label Cohort Study. Ann Oncol (2020) 31:S1307. doi: 10.1016/j.annonc.2020.10.195;

48: Li CJ, Zhou J. Initial Report of a Two-Stage Resection for Hepatocellular Carcinoma Following Downstaging With Transarterial Chemoembolization and Sorafenib. Fubu Waike (2017) 30:295-8+301. doi: 10.3969/j.issn.1003-5591.2017.04.015.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors, systematic review

Citation: Ke Q, Xin F, Fang H, Zeng Y, Wang L and Liu J (2022) Corrigendum: The Significance of Transarterial Chemo(embolization) Combined With Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front. Immunol. 13:952446. doi: 10.3389/fimmu.2022.952446

Received: 25 May 2022; Accepted: 26 May 2022;
Published: 07 June 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Ke, Xin, Fang, Zeng, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yongyi Zeng, lamp197311@126.com; Lei Wang, wangleiy001@126.com; Jingfeng Liu, drjingfeng@126.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.